BioXcel Therapeutics (FRA:BX2) Change In Payables And Accrued Expense : €6.55 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Change In Payables And Accrued Expense?

BioXcel Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was €3.87 Mil. It means BioXcel Therapeutics's Accounts Payable & Accrued Expense increased by €3.87 Mil from Dec. 2023 to Mar. 2024 .

BioXcel Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €-0.66 Mil. It means BioXcel Therapeutics's Accounts Payable & Accrued Expense declined by €0.66 Mil from Dec. 2022 to Dec. 2023 .

BioXcel Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for BioXcel Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Change In Payables And Accrued Expense Chart

BioXcel Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

3.38

2.63

4.29

15.89

-0.66

BioXcel Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-3.23	6.96	5.79	-10.06	3.87

BioXcel Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.55 Mil.

BioXcel Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics (FRA:BX2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

BTAI:USA BX2:Germany

Address

555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics (FRA:BX2) Headlines

No Headlines